Compounds > r18 peptide

Page last updated: 2024-11-12

r18 peptide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

R18 peptide: a 20-mer peptide, derived from a phage library, that binds 14-3-3 tau protein; amino acid sequence in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	16138697
CHEMBL ID	3814675
MeSH ID	M0519664

Synonyms (3)

Synonym
r18 peptide
CHEMBL3814675 ,
bdbm50177028

Research Excerpts

Toxicity

Excerpt	Reference	Relevance
" In vitro studies demonstrated that R18 and R18D were most toxic to neurons, followed by astrocytes, HEK293 and bEND."	( Comparison of neuroprotective efficacy of poly-arginine R18 and R18D (D-enantiomer) peptides following permanent middle cerebral artery occlusion in the Wistar rat and in vitro toxicity studies. Anderton, RS; Bakeberg, MC; Blacker, DJ; Clark, VW; Cross, JL; Knuckey, NW; Meloni, BP; Milani, D, 2018)	0.48
"5 and 1 µM) reduced the toxic effects of rtPA and OGD/rtPA, while on some occasions a higher 2 µM R18D concentrations exacerbated neuronal and bEnd."	( Assessment of recombinant tissue plasminogen activator (rtPA) toxicity in cultured neural cells and subsequent treatment with poly-arginine peptide R18D. Anderton, RS; Kenna, JE; Knuckey, NW; Meloni, BP, 2020)	0.56

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (3)

Activation Measurements

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
14-3-3 protein theta	Homo sapiens (human)	Kd	0.0700	0.0700	0.0700	0.0700	AID1304818
14-3-3 protein beta/alpha	Homo sapiens (human)	Kd	0.0700	0.0700	0.0700	0.0700	AID1304817
14-3-3 protein eta	Homo sapiens (human)	Kd	0.0700	0.0700	0.0700	0.0700	AID1304819
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (22)

Process	via Protein(s)	Taxonomy
protein targeting	14-3-3 protein theta	Homo sapiens (human)
small GTPase-mediated signal transduction	14-3-3 protein theta	Homo sapiens (human)
substantia nigra development	14-3-3 protein theta	Homo sapiens (human)
negative regulation of monoatomic ion transmembrane transport	14-3-3 protein theta	Homo sapiens (human)
negative regulation of DNA-templated transcription	14-3-3 protein theta	Homo sapiens (human)
signal transduction	14-3-3 protein theta	Homo sapiens (human)
protein localization	14-3-3 protein theta	Homo sapiens (human)
protein targeting	14-3-3 protein beta/alpha	Homo sapiens (human)
negative regulation of protein dephosphorylation	14-3-3 protein beta/alpha	Homo sapiens (human)
positive regulation of catalytic activity	14-3-3 protein beta/alpha	Homo sapiens (human)
negative regulation of G protein-coupled receptor signaling pathway	14-3-3 protein beta/alpha	Homo sapiens (human)
cytoplasmic sequestering of protein	14-3-3 protein beta/alpha	Homo sapiens (human)
signal transduction	14-3-3 protein beta/alpha	Homo sapiens (human)
protein localization	14-3-3 protein beta/alpha	Homo sapiens (human)
regulation of sodium ion transport	14-3-3 protein eta	Homo sapiens (human)
glucocorticoid catabolic process	14-3-3 protein eta	Homo sapiens (human)
intracellular protein transport	14-3-3 protein eta	Homo sapiens (human)
substantia nigra development	14-3-3 protein eta	Homo sapiens (human)
intracellular glucocorticoid receptor signaling pathway	14-3-3 protein eta	Homo sapiens (human)
regulation of neuron differentiation	14-3-3 protein eta	Homo sapiens (human)
positive regulation of DNA-templated transcription	14-3-3 protein eta	Homo sapiens (human)
regulation of synaptic plasticity	14-3-3 protein eta	Homo sapiens (human)
negative regulation of dendrite morphogenesis	14-3-3 protein eta	Homo sapiens (human)
membrane depolarization during action potential	14-3-3 protein eta	Homo sapiens (human)
presynaptic modulation of chemical synaptic transmission	14-3-3 protein eta	Homo sapiens (human)
regulation of sodium ion transmembrane transporter activity	14-3-3 protein eta	Homo sapiens (human)
signal transduction	14-3-3 protein eta	Homo sapiens (human)
protein localization	14-3-3 protein eta	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (16)

Process	via Protein(s)	Taxonomy
protein binding	14-3-3 protein theta	Homo sapiens (human)
protein domain specific binding	14-3-3 protein theta	Homo sapiens (human)
identical protein binding	14-3-3 protein theta	Homo sapiens (human)
transmembrane transporter binding	14-3-3 protein theta	Homo sapiens (human)
14-3-3 protein binding	14-3-3 protein theta	Homo sapiens (human)
protein kinase inhibitor activity	14-3-3 protein beta/alpha	Homo sapiens (human)
protein binding	14-3-3 protein beta/alpha	Homo sapiens (human)
enzyme binding	14-3-3 protein beta/alpha	Homo sapiens (human)
protein domain specific binding	14-3-3 protein beta/alpha	Homo sapiens (human)
identical protein binding	14-3-3 protein beta/alpha	Homo sapiens (human)
histone deacetylase binding	14-3-3 protein beta/alpha	Homo sapiens (human)
cadherin binding	14-3-3 protein beta/alpha	Homo sapiens (human)
phosphoserine residue binding	14-3-3 protein beta/alpha	Homo sapiens (human)
phosphoprotein binding	14-3-3 protein beta/alpha	Homo sapiens (human)
actin binding	14-3-3 protein eta	Homo sapiens (human)
insulin-like growth factor receptor binding	14-3-3 protein eta	Homo sapiens (human)
protein binding	14-3-3 protein eta	Homo sapiens (human)
sodium channel regulator activity	14-3-3 protein eta	Homo sapiens (human)
enzyme binding	14-3-3 protein eta	Homo sapiens (human)
protein domain specific binding	14-3-3 protein eta	Homo sapiens (human)
nuclear glucocorticoid receptor binding	14-3-3 protein eta	Homo sapiens (human)
identical protein binding	14-3-3 protein eta	Homo sapiens (human)
transmembrane transporter binding	14-3-3 protein eta	Homo sapiens (human)
protein heterodimerization activity	14-3-3 protein eta	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (14)

Process	via Protein(s)	Taxonomy
cytoplasm	14-3-3 protein theta	Homo sapiens (human)
cytosol	14-3-3 protein theta	Homo sapiens (human)
focal adhesion	14-3-3 protein theta	Homo sapiens (human)
membrane	14-3-3 protein theta	Homo sapiens (human)
synapse	14-3-3 protein theta	Homo sapiens (human)
extracellular exosome	14-3-3 protein theta	Homo sapiens (human)
protein-containing complex	14-3-3 protein theta	Homo sapiens (human)
cytoplasm	14-3-3 protein theta	Homo sapiens (human)
cytoplasm	14-3-3 protein beta/alpha	Homo sapiens (human)
vacuolar membrane	14-3-3 protein beta/alpha	Homo sapiens (human)
cytosol	14-3-3 protein beta/alpha	Homo sapiens (human)
focal adhesion	14-3-3 protein beta/alpha	Homo sapiens (human)
membrane	14-3-3 protein beta/alpha	Homo sapiens (human)
melanosome	14-3-3 protein beta/alpha	Homo sapiens (human)
perinuclear region of cytoplasm	14-3-3 protein beta/alpha	Homo sapiens (human)
extracellular exosome	14-3-3 protein beta/alpha	Homo sapiens (human)
cytoplasm	14-3-3 protein beta/alpha	Homo sapiens (human)
cytoplasm	14-3-3 protein eta	Homo sapiens (human)
cytosol	14-3-3 protein eta	Homo sapiens (human)
plasma membrane	14-3-3 protein eta	Homo sapiens (human)
intercalated disc	14-3-3 protein eta	Homo sapiens (human)
extracellular exosome	14-3-3 protein eta	Homo sapiens (human)
presynapse	14-3-3 protein eta	Homo sapiens (human)
cerebellar granule cell to Purkinje cell synapse	14-3-3 protein eta	Homo sapiens (human)
cytoplasm	14-3-3 protein eta	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (3)

Assay ID	Title	Year	Journal	Article
AID1304819	Binding affinity to GST-tagged 125I-labelled 14-3-3eta (unknown origin) expressed in Escherichia coli by solid phase assay	2016	Bioorganic & medicinal chemistry, Aug-01, Volume: 24, Issue:15	Small molecules that target phosphorylation dependent protein-protein interaction.
AID1304818	Binding affinity to GST-tagged 125I-labelled full length human 14-3-3tau expressed in Escherichia coli by solid phase assay	2016	Bioorganic & medicinal chemistry, Aug-01, Volume: 24, Issue:15	Small molecules that target phosphorylation dependent protein-protein interaction.
AID1304817	Binding affinity to GST-tagged 125I-labelled 14-3-3beta (unknown origin) expressed in Escherichia coli by solid phase assay	2016	Bioorganic & medicinal chemistry, Aug-01, Volume: 24, Issue:15	Small molecules that target phosphorylation dependent protein-protein interaction.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (7.69)	29.6817
2010's	9 (69.23)	24.3611
2020's	3 (23.08)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 18.33

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	18.33 (24.57)
Research Supply Index	2.64 (2.92)
Research Growth Index	5.78 (4.65)
Search Engine Demand Index	10.37 (26.88)
Search Engine Supply Index	2.00 (0.95)

This Compound (18.33)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	1 (7.69%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	12 (92.31%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
uridine [no description available]	2.08	1	uridines	drug metabolite; fundamental metabolite; human metabolite
ethylene Plastipore: high density polyethylene sponge biocompatible material; used as posts in dental bridges	2.08	1	alkene; gas molecular entity	plant hormone; refrigerant
pyrroles 1H-pyrrole : A tautomer of pyrrole that has the double bonds at positions 2 and 4.. pyrrole : A five-membered monocyclic heteroarene comprising one NH and four CH units which forms the parent compound of the pyrrole group of compounds. Its five-membered ring structure has three tautomers. A 'closed class'.. azole : Any monocyclic heteroarene consisting of a five-membered ring containing nitrogen. Azoles can also contain one or more other non-carbon atoms, such as nitrogen, sulfur or oxygen.	2.04	1	pyrrole; secondary amine
perylene Perylene: A 20-carbon dibenz(de,kl)anthracene that can be viewed as a naphthalene fused to a phenalene or as dinaphthalene. It is used as fluorescent lipid probe in the cytochemistry of membranes and is a polycyclic hydrocarbon pollutant in soil and water. Derivatives may be carcinogenic.. perylene : An ortho- and peri-fused polycyclic arene comprising of five benzene rings that is anthracene in which the d,e and k,l sides are fused to benzene rings.	2.08	1	ortho- and peri-fused polycyclic arene; perylenes
poloxalene Poloxalene: A copolymer of polyethylene and polypropylene ether glycol. It is a non-ionic polyol surface-active agent used medically as a fecal softener and in cattle for prevention of bloat.. pluronic : A triblock copolymer composed of a central hydrophobic chain of poly(propylene oxide) flanked by two hydrophilic chains of poly(ethylene oxide).	2.1	1	epoxide
imatinib mesylate imatinib methanesulfonate : A methanesulfonate (mesylate) salt that is the monomesylate salt of imatinib. Used for treatment of chronic myelogenous leukemia and gastrointestinal stromal tumours.	2.04	1	methanesulfonate salt	anticoronaviral agent; antineoplastic agent; apoptosis inducer; tyrosine kinase inhibitor
u 0126 U 0126: protein kinase kinase inhibitor; structure in first source	2.04	1	aryl sulfide; dinitrile; enamine; substituted aniline	antineoplastic agent; antioxidant; apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; osteogenesis regulator; vasoconstrictor agent
sirolimus Sirolimus: A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to IMMUNOPHILINS. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties.. sirolimus : A macrolide lactam isolated from Streptomyces hygroscopicus consisting of a 29-membered ring containing 4 trans double bonds, three of which are conjugated. It is an antibiotic, immunosupressive and antineoplastic agent.	2.04	1	antibiotic antifungal drug; cyclic acetal; cyclic ketone; ether; macrolide lactam; organic heterotricyclic compound; secondary alcohol	antibacterial drug; anticoronaviral agent; antineoplastic agent; bacterial metabolite; geroprotector; immunosuppressive agent; mTOR inhibitor
endothelin-1 Endothelin-1: A 21-amino acid peptide produced in a variety of tissues including endothelial and vascular smooth-muscle cells, neurons and astrocytes in the central nervous system, and endometrial cells. It acts as a modulator of vasomotor tone, cell proliferation, and hormone production. (N Eng J Med 1995;333(6):356-63)	2.21	1
chitosan [no description available]	2.13	1
tat-nr2b9c Tat-NR2B9c: a synthetic peptide consisting of the C-terminal 9 amino acids of the NR2B subunit of the NMDA receptor fused to the cell membrane protein transduction domain of the HIV-1-Tat protein	2.58	2
gx 15-070 obatoclax: a pan-Bcl-2 inhibitor potentially useful in treating mantle cell lymphoma	2.04	1

Condition	Relationship Strength	Studies
Apoplexy [description not available]	2.89	3
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.59	2
Stroke A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)	2.89	3
Carotid Arteriopathies, Traumatic [description not available]	2.15	1
Cerebral Infarction, Middle Cerebral Artery [description not available]	2.57	2
Brain Swelling [description not available]	2.57	2
Cerebral Ischemia [description not available]	2.15	1
Anterior Circulation Transient Ischemic Attack [description not available]	2.15	1
Brain Vascular Disorders [description not available]	2.15	1
Brain Edema Increased intracellular or extracellular fluid in brain tissue. Cytotoxic brain edema (swelling due to increased intracellular fluid) is indicative of a disturbance in cell metabolism, and is commonly associated with hypoxic or ischemic injuries (see HYPOXIA, BRAIN). An increase in extracellular fluid may be caused by increased brain capillary permeability (vasogenic edema), an osmotic gradient, local blockages in interstitial fluid pathways, or by obstruction of CSF flow (e.g., obstructive HYDROCEPHALUS). (From Childs Nerv Syst 1992 Sep; 8(6):301-6)	2.57	2
Brain Ischemia Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION.	2.15	1
Ischemic Attack, Transient Brief reversible episodes of focal, nonconvulsive ischemic dysfunction of the brain having a duration of less than 24 hours, and usually less than one hour, caused by transient thrombotic or embolic blood vessel occlusion or stenosis. Events may be classified by arterial distribution, temporal pattern, or etiology (e.g., embolic vs. thrombotic). (From Adams et al., Principles of Neurology, 6th ed, pp814-6)	2.15	1
Cerebrovascular Disorders A spectrum of pathological conditions of impaired blood flow in the brain. They can involve vessels (ARTERIES or VEINS) in the CEREBRUM, the CEREBELLUM, and the BRAIN STEM. Major categories include INTRACRANIAL ARTERIOVENOUS MALFORMATIONS; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; and others.	2.15	1
Infarction, Middle Cerebral Artery NECROSIS occurring in the MIDDLE CEREBRAL ARTERY distribution system which brings blood to the entire lateral aspects of each CEREBRAL HEMISPHERE. Clinical signs include impaired cognition; APHASIA; AGRAPHIA; weak and numbness in the face and arms, contralaterally or bilaterally depending on the infarction.	2.57	2
Brain Damage, Chronic A condition characterized by long-standing brain dysfunction or damage, usually of three months duration or longer. Potential etiologies include BRAIN INFARCTION; certain NEURODEGENERATIVE DISORDERS; CRANIOCEREBRAL TRAUMA; ANOXIA, BRAIN; ENCEPHALITIS; certain NEUROTOXICITY SYNDROMES; metabolic disorders (see BRAIN DISEASES, METABOLIC); and other conditions.	2.17	1
Malignant Melanoma [description not available]	2.1	1
Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)	2.1	1

chemdatabank.com